| Literature DB >> 18839433 |
Aurélien Marabelle1, Vincent Sapin, Raphaël Rousseau, Brigitte Periquet, François Demeocq, Justyna Kanold.
Abstract
We report 19 episodes of hypercalcemia in three children treated with 13-cis-retinoic acid (13-cis-RA) as a post-consolidation therapy for high-risk neuroblastoma. There was no concomitant overload in 13-cis-RA blood levels. Blood calcium fell after arrest of 13-cis-RA intake. Half dosage retinoid treatment resumption did not prevent the recurrence of hypercalcemia. Concomitant biological values showed massive bone resorption. Hence, hypercalcemia seemed not secondary to 13-cis-RA overload but rather to inter-individual variability in its interaction with bone metabolism. Current guidelines in case of hypercalcemia are to reduce 13-cis-RA dosage. Instead we propose to maintain the therapeutic dosage, but to shorten the duration of courses. (c) 2008 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2009 PMID: 18839433 DOI: 10.1002/pbc.21768
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN: 1545-5009 Impact factor: 3.167